These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37717927)

  • 21. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis.
    Lee H; Park S; Kang JE; Lee HM; Kim SA; Rhie SJ
    Sci Rep; 2020 Jan; 10(1):530. PubMed ID: 31953463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer.
    Yang M; Qu H; Liu A; Liu J; Sun P; Li H
    J Cancer Res Ther; 2019; 15(7):1561-1566. PubMed ID: 31939438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in Breast Cancer Patients].
    Kang Y; Shiraki E; Tsuyuki S
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1427-1431. PubMed ID: 31530783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study.
    Seki H; Higeta K; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
    Clin Breast Cancer; 2022 Apr; 22(3):235-243. PubMed ID: 34289949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
    Su W; Zhang S; Li C; Hao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):379-82. PubMed ID: 26463031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
    Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.
    Yoneshima Y; Morita S; Ando M; Nakamura A; Iwasawa S; Yoshioka H; Goto Y; Takeshita M; Harada T; Hirano K; Oguri T; Kondo M; Miura S; Hosomi Y; Kato T; Kubo T; Kishimoto J; Yamamoto N; Nakanishi Y; Okamoto I
    J Thorac Oncol; 2021 Sep; 16(9):1523-1532. PubMed ID: 33915251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
    Bi Z; Chen P; Liu YB; Zhao T; Sun X; Song XR; Wang YS
    Breast Cancer Res Treat; 2020 Nov; 184(2):397-405. PubMed ID: 32776291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
    Lv ZD; Song HM; Niu ZH; Nie G; Zheng S; Xu YY; Gong W; Wang HB
    Front Oncol; 2021; 11():760655. PubMed ID: 35087749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review.
    Pellegrino B; Boggiani D; Tommasi C; Palli D; Musolino A
    Acta Biomed; 2017 Oct; 88(3):329-333. PubMed ID: 29083340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
    Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
    Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
    Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ;
    Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study).
    Futamura M; Oba M; Masuda N; Bando H; Okada M; Yamamoto Y; Kin T; Saeki T; Nagashima T; Kuwayama T; Toh U; Hirano A; Inokuchi M; Yamagami K; Mizuno Y; Kojima Y; Nakayama T; Yasojima H; Ohno S
    Breast Cancer; 2021 Sep; 28(5):1023-1037. PubMed ID: 33811599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
    Megerdichian C; Olimpiadi Y; Hurvitz SA
    Cancer Treat Rev; 2014 Jun; 40(5):614-25. PubMed ID: 24560997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.
    Mrózek E; Layman R; Ramaswamy B; Lustberg M; Vecchione A; Knopp MV; Shapiro CL
    Clin Breast Cancer; 2014 Aug; 14(4):228-34. PubMed ID: 24703985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
    Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.